Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
IPF and PDE4B Inhibitors
Dr Nathan highlights the role of PDE4B inhibitors in IPF management.
EP: 1.Emerging Agents in IPF Treatment
Now Viewing
EP: 2.IPF and PDE4B Inhibitors
EP: 3.Importance of Patient-Reported Outcomes
EP: 4.Future Possibilities in IPF Treatment
EP: 5.Advice for Clinicians Treating IPF
EP: 6.Current Standard of Care in IPF
EP: 7.Therapeutic Response and Disease Progression
EP: 8.Key Considerations for Selecting IPF Treatment
EP: 9.Economic Impact of IPF
EP: 10.Unmet Needs in IPF Landscape
EP: 11.Overview of Idiopathic Pulmonary Fibrosis (IPF)
EP: 12.Impact of IPF on Quality of Life and Financial Considerations
EP: 13.Diagnosing IPF: Key Tests, Time to Diagnosis, and Importance of Early Detection
EP: 14.Clinical Presentation and Risk Factors
EP: 15.Impact of Comorbidities on IPF Management
EP: 16.Overcoming Treatment Barriers: Strategies for Success
EP: 17.Impact of Treatment Delays on Patient Outcomes
Video content above is prompted by the following:
- What is the rationale for studying the phosphodiesterase 4 (PDE4) inhibitor pathway in idiopathic pulmonary fibrosis (IPF)?
- How do PDE4 inhibitors differ from PDE4B inhibitors?
- Why is this pathway of interest to pulmonologists and patients living with IPF?
Related Videos
Related Content
